COVID-19 Vaccine Manufacturing: Moderna CEO Worries Most About Raw Materials
Moderna's Bencal and Merck Vaccine head Markels discuss the difficulties in scaling up manufacturing capacity for vaccine candidates at BIO plenary session; CEPI CEO says his organization can help facilitate pairing of vaccine development partners.
You may also be interested in...
Neutralizing antibodies were seen in all 45 people injected across three dose levels in the first-in-human study. The middle dose of 100mcg will be tested in the company’s Phase III trial starting 27 July.
Ease of manufacturing scale up may determine which candidates advance furthest in the US government's partnership with industry to speed COVID-19 vaccines to patients. Senior government officials also discussed approval standards, how a vaccine would be distributed, and how much the government and Americans could pay in a 16 June press call.
The latest global vaccines summit has seen the launch of a new mechanism designed to spur the development of new coronavirus vaccines and ensure they are made available, particularly in low- and middle-income countries.